Work

Abstract LB162: Tinengotinib in patients with advanced solid tumors harboring actionable FGFR1-3 mutations

Year: 2024

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2024-lb162

Authors: Sarina A. Piha-Paul, Chih-Yi "Andy" Liao, Lionel Fonkoua, Amit MahipaI, Sanjay Goel, Christos Fountzilas, Lin Shen, Daneng Li, Dustin Deming, Farshid Dayyani, Weiqing Han, Zuoxing Niu, Jean Fan, Peng Peng, Hui Wang, Peng Huang, Frank Wu, Milind Javle

Institutions: The University of Texas MD Anderson Cancer Center, University of Chicago, Mayo Clinic, University Hospitals Cleveland Medical Center, Rutgers Cancer Institute, Roswell Park Comprehensive Cancer Center, Peking University Cancer Hospital, City Of Hope National Medical Center, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, University of California, Irvine, Hunan Cancer Hospital, Shandong Tumor Hospital

Language: English

Topic: Fibroblast Growth Factor Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4393987531

Cites:

Cited by:

Related to: 10